Birmingham, Alabama, USA, November 13, 2026
Molecular Designs has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its SimplicityDx™ Panel FluA/FluB/RSV, marking the company’s first FDA-cleared molecular diagnostic assay. The newly cleared test is designed to detect and differentiate influenza A, influenza B and respiratory syncytial virus (RSV) in anterior nasal swab specimens collected from individuals experiencing signs and symptoms of respiratory tract infections. The regulatory milestone represents an important development for the company and strengthens its position in the molecular infectious disease diagnostics market. The multiplex real-time reverse transcription polymerase chain reaction (RT-PCR) assay enables laboratories to test for three major respiratory pathogens within a single testing run, supporting more efficient differential diagnosis during respiratory infection seasons. Influenza and RSV frequently circulate simultaneously, creating increased demand for reliable laboratory testing and timely identification of respiratory pathogens. By combining multiple viral targets in one assay, the SimplicityDx panel aims to help clinical laboratories streamline testing workflows, manage seasonal testing demand and support healthcare professionals in making informed diagnostic decisions. The clearance was granted under FDA 510(k) number K262789.
FDA 510(k) Clearance Supports Multiplex Respiratory Testing
The newly cleared SimplicityDx Panel FluA/FluB/RSV uses multiplex real-time RT-PCR technology to qualitatively detect and distinguish RNA from influenza A, influenza B and RSV. The test is intended for anterior nasal swab specimens obtained from individuals with symptoms of respiratory tract infection. Its multiplex design allows laboratories to identify three important respiratory pathogens through a single molecular testing workflow rather than performing separate tests for each virus. This capability is particularly relevant during seasonal respiratory outbreaks, when influenza and RSV infections can present with similar clinical symptoms. Accurate identification of the causative pathogen can help healthcare professionals make appropriate patient-management decisions alongside clinical evaluation and other laboratory findings. The assay also includes an internal control to support monitoring of the testing process. Molecular Designs stated that the test was developed to meet the practical requirements of clinical laboratories, with a focus on workflow efficiency, testing flexibility and reliable laboratory operations. The FDA clearance represents a significant achievement for the company as it transitions its respiratory diagnostic technology into the regulated clinical testing market.
Breakaway Format Designed to Improve Laboratory Efficiency
One of the distinguishing features of the SimplicityDx panel is its breakaway test format, which allows laboratories to use only the tests required for each testing run. This design is intended to reduce unnecessary reagent consumption, minimise waste and simplify inventory management. Unlike testing formats that require laboratories to use a complete fixed panel for every run, the breakaway configuration provides greater flexibility when testing volumes fluctuate. This can be particularly useful during respiratory seasons, when laboratory demand may increase significantly over short periods. The assay is also designed to minimise pipetting requirements, helping reduce manual handling and simplify routine laboratory procedures. Additionally, the format supports batch processing, allowing higher-volume laboratories to process multiple samples efficiently during periods of increased demand. The panel is designed to work with Molecular Designs’ Simplicity Dx Extraction products, creating an integrated workflow for respiratory pathogen testing. These features may be especially valuable for laboratories managing staffing constraints, variable sample volumes and seasonal inventory requirements. By considering practical laboratory operations alongside analytical testing capabilities, Molecular Designs aims to provide a diagnostic solution that supports both workflow flexibility and operational efficiency.
Molecular Designs Expands Its Molecular Diagnostics Portfolio
The FDA clearance marks an important milestone in the development of Molecular Designs’ molecular diagnostics portfolio. Founded by physicians, the Birmingham-based company develops and manufactures PCR-based diagnostic assays, components, reagents and instrumentation for infectious disease testing. Its manufacturing and quality operations are based on Good Manufacturing Practice (GMP) and ISO 13485:2016 quality standards, supporting its focus on regulated medical diagnostic products. The SimplicityDx Panel FluA/FluB/RSV is intended for prescription use only and is restricted to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing. The company believes that the new clearance will help expand access to practical molecular testing solutions for clinical laboratories across the United States. The launch also reflects the broader importance of multiplex molecular diagnostics in infectious disease management, where identifying multiple pathogens through a single assay can support more efficient testing strategies. By securing its first FDA 510(k) clearance, Molecular Designs has achieved a significant regulatory milestone and strengthened its presence in the clinical molecular diagnostics sector. The SimplicityDx respiratory panel provides laboratories with another option for detecting influenza A, influenza B and RSV, particularly during periods of increased respiratory infection activity.
Source: Molecular Designs press release



